ArticleRheumatology advances in practice2026
Pre-treatment serum albumin predicts relapse in idiopathic inflammatory myopathies: a retrospective cohort study with cytokine profiling.
Article in Rheumatology advances in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify predictors of relapse in patients with idiopathic inflammatory myopathies (IIMs) and investigate the biological mechanisms underlying these associations using cytokine profiling. Methods: We conducted a retrospective study of 99 patients who achieved remission after initial treatment for IIMs or myositis-specific antibody-positive interstitial lung disease at Nagasaki University Hospital. Among 197 diagnosed patients, we included those who achieved clinical improvement and were followed up for ≥3 months, excluding early deaths and those with insufficient follow-up. Relapse was defined as disease worsening requiring treatment intensification. Risk factors were analyzed using the Cox regression analysis. Serum cytokine profiles were compared between patients with low and high pre-treatment albumin levels. Results: Forty-one patients (41%) relapsed. Multivariate analysis revealed that pretreatment albumin level remained the only independent predictor of overall relapse (HR, 0.60; 95% CI: 0.40-0.92, Conclusion: Pretreatment albumin levels independently predict relapse in IIMs, and cytokine profiling demonstrates that low albumin levels reflect active systemic inflammation. These findings support the use of albumin as a practical biomarker for risk stratification in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.